Vol 10 Issue 4

Download PDF

Featuring

Issue Spotlight: Cell therapy upstream processing and materials
Other articles
Webinars

Cell therapy upstream processing and materials

Guest Editor:

Isabelle Rivière, Vice President, Head of Oncology Cell Therapy Technologies and Product Engineer at Takeda

Expert Insight

The sweet cell of success: key considerations for the sourcing and production of pluripotent cell lines for therapeutic development

Samuel JI Blackford, Nathan C Manley

21 May

Read

Raw materials and supplies for cell therapies: end to end expectations and best practices

Lili Belcastro

15 May

Read

Innovator Insight

G-Rex bioreactors incubated in Heracell™ Vios™ CR CO<sub>2</sub> Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

G-Rex bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

M Kay Bates, D Fick, J Schneider et al.

12 June

Read

An automated 24-hour CAR-T manufacturing process

Mina Ahmadi

8 May

Read

Commentary

De-risking pluripotent stem cell therapies

Stephen Sullivan, Ricardo Baptista

18 June

Read

Interview

Planning for success with an allogeneic Treg cell sourcing strategy

Matthew Breton

23 May

Read

Weighing up the pros and cons of adopting a piecemeal versus a full automation approach to cell therapy manufacture

Raymond Luke

21 May

Read

Viewpoint

Enabling affordable access to CAR-T cell and other cellular gene therapy products

R Orentas, Y Xiong, I Oparaocha et al.

13 May

Read

Journal articles

Innovator Insight

Accelerating cell therapy production: realizing the advantages of rapid analytical testing solutions

Seth Peterson

7 May

Read

Enabling and optimizing perfusion for intensified production of CAR-T cells in stirred tank bioreactors

Qasim Rafiq, Julia Hengst

15 May

Read

Interview

Fit for function: developing potency assays reflective of the <i>in vivo</i> environment

Fit for function: developing potency assays reflective of the in vivo environment

Giorgio Zenere, Dirk Windgassen

10 May

Read

FastFacts

T cell culture process development in stirred-tank bioreactors

Stefan Schlößer

21 May

Read

Intensified production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration

Béla Brühlmann, Sven Göbel

23 May

Read

How to build an AAV platform that produces higher titers and percent full capsids

Leisha Kopp, Chris Brown

1 May

Watch

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

Akshaya Chandrasekaran

2 May

Watch

Think ahead: preparing for challenges to accelerate your cell therapy commercialization

S Ghassemi, S Carmichael, K Henckels et al.

15 May

Watch

From process development to manufacturing: how to successfully optimize and scale up the AAV enrichment step on novel CIMmultus QA HR line

Rok Žigon, Maja Leskovec

16 May

Watch

Achieving comprehensive analysis and characterization of extracellular vesicles

Alex Shephard

29 May

Watch

Revolutionary innovations are underway to industrialize cell and gene therapies

Mark Santos

13 June

Watch

Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

Alan Gutowski, Joanna Kern

CELL AND GENE THERAPY INSIGHTS

May 2024 Issue

Vol 10 Issue 4

Featuring

SPOTLIGHT

Cell therapy upstream processing and materials

Expert Insight

The sweet cell of success: key considerations for the sourcing and production of pluripotent cell lines for therapeutic development

Raw materials and supplies for cell therapies: end to end expectations and best practices

Innovator Insight

G-Rex bioreactors incubated in Heracell™ Vios™ CR CO2 Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

An automated 24-hour CAR-T manufacturing process

Commentary

De-risking pluripotent stem cell therapies

Interview

Planning for success with an allogeneic Treg cell sourcing strategy

Weighing up the pros and cons of adopting a piecemeal versus a full automation approach to cell therapy manufacture

Viewpoint

Enabling affordable access to CAR-T cell and other cellular gene therapy products

Journal articles

Innovator Insight

Accelerating cell therapy production: realizing the advantages of rapid analytical testing solutions

Enabling and optimizing perfusion for intensified production of CAR-T cells in stirred tank bioreactors

Interview

Fit for function: developing potency assays reflective of the in vivo environment

FastFacts

T cell culture process development in stirred-tank bioreactors

Intensified production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration

Leveraging rapid sterility testing to advance cell therapy production

Efficient AAV purification with AAVX and AAV9 magnetic beads

Webinars

﻿Entering the fast lane of assay validation for cell and gene therapies

Maximizing process control and efficiency in CAR-T cell manufacturing

HEK293 residual DNA testing in cell and gene therapy

How to build an AAV platform that produces higher titers and percent full capsids

Enhancing CAR-T cell generation: optimizing non-viral engineering of resting T cells for improved cancer immunotherapy

﻿Think ahead: preparing for challenges to accelerate your cell therapy commercialization

From process development to manufacturing: how to successfully optimize and scale up the AAV enrichment step on novel﻿ CIMmultus QA HR line

Achieving comprehensive analysis and characterization of extracellular vesicles

Revolutionary innovations are underway to industrialize cell and gene therapies

Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

G-Rex bioreactors incubated in Heracell™ Vios™ CR CO₂ Incubators help prevent cross contamination and bacterial contamination in cell and gene modified cell therapy production

Entering the fast lane of assay validation for cell and gene therapies

Think ahead: preparing for challenges to accelerate your cell therapy commercialization

From process development to manufacturing: how to successfully optimize and scale up the AAV enrichment step on novel CIMmultus QA HR line